How Easy is to Get an IND from FDA for a COVID-19 Drugs? 

Typically, an IND application requires months and years of research and development, and a reasonable rationale for the potential treatment. Since the announcement of the pandemic about 2-3 months ago, there have been hundreds of clinical trials initiated for products intended to treat or prevent the disease. This may seem like an awfully short time … Read more

Pandemic is Boom Time of Digital Health Companies

The “Stay at Home” orders have created a once-in-a-lifetime opportunity for information tech companies to build and test digital health tools that would live way beyond the pandemic. All those concerns for privacy and of digital health companies exploiting our personal health information for their financial gains have gone out the window while government, political … Read more

FDA Warns Antibody Based COVID-19 Tests Are Not “Approved”

In about 3 weeks since FDA announced a policy under which serological tests could be sold with just a notification of intent to file an EUA, more than 70 companies have filed this notification and started selling diagnostic tests that measure anti-coronavirus antibodies. However, these tests must carry a disclaimer that the test has not … Read more

Is FDA Too Slow to Deal With a Pandemic?

In the last two months, FDA has announced, proposed, and implemented several measures to address the ongoing pandemic, but questions are being raised about the perceived slow speed at which FDA acts in an emergency. There have been complaints of FDA taking too long to authorize diagnostic tests and making decisions on the Emergency Use … Read more

How Long Should It Take to Develop a Treatment for COVID-19?

The burning question in all circles of the society is when and how would a treatment or vaccine for COVID-19 emerge. The politicians and public would want it done in days and weeks, the scientists and developers need months and years. The vaccine is projected to take at least about 12-18 months to be ready … Read more

Can You Rescind an Orphan Designation? Lessons from Gilead-FDA

This week Gilead’s decision to ask FDA to rescind its orphan drug designation for its COVID-19 drug highlighted the loophole in the overall rules for orphan drug designations. Unlike all other expedited approval designations, orphan drugs designations (ODD), once granted by the FDA cannot be rescinded by the FDA, under almost all circumstances. Gilead reportedly … Read more

FDA Launches New Nutritional Label Education Campaign

In the last few years, the nutritional labels for foods have gone through major revisions. Proper nutrition is critically dependent on the consumer’s ability to understand the nutritional content of the food they consume. And it is even more important in times of limited mobility such as these days with the travel and movement restrictions … Read more

FDA Guidance for Trials in Pandemic Hints that Virtual Clinical Trials Are Least Affected

Most ongoing clinical trials in the US have been suspended indefinitely, and no new trials are being initiated due to the COVID-19 pandemic. FDA advices measures like those implemented during a temporary clinical hold in such circumstances. With shelter at home advisory and mandatory quarantine in place in most places in the country, clinics must … Read more